Clozaril superiority claim?
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee will review Novartis'Clozaril (clozapine) for treatment of suicidality in patients with schizophrenia or schizoaffective disorders Nov. 4. The review will focus on a head-to-head study versus Lilly's Zyprexa (olanzapine). The meeting will take place at the Holiday Inn, Gaithersburg, Md. [To sign up for a webcast of this meeting, visit 1FDAAdvisoryCommittee.com.]...
You may also be interested in...
Abbott Launches Five-Minute POC Rapid COVID-19 Test
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
In A Bizarre Move, Trump Orders GM To Make Ventilators – Even Though The Auto Giant Already Is
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Start-Up Spotlight: Iraq War Veteran Deploys ‘Bone Paint’ To Combat Traumatic Injuries
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: